Quote | Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT)
Last: | $0.099 |
---|---|
Change Percent: | -66.1% |
Open: | $0.136 |
Close: | $0.292 |
High: | $0.14 |
Low: | $0.095 |
Volume: | 13,035,456 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT)
Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ), a pharmaceutical company dedicated to providing solutions to un...
Clarus Therapeutics ( OTCPK:CRXT ) filed voluntary petitions under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware and want to pursue an auction and sale of its only commercial asset Jatenzo. Jatenzo is approved to treat testosterone deficiency i...
Message Board Posts | Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Clarus Therapeutics Holdings Inc. Company Name:
CRXT Stock Symbol:
NASDAQ Market:
Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ), a pharmaceutical company dedicated to providing solutions to un...
NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary ...